Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
22
11
2022
revised:
30
12
2022
accepted:
24
02
2023
medline:
2
5
2023
pubmed:
15
4
2023
entrez:
14
4
2023
Statut:
ppublish
Résumé
Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. In this retrospective analysis, investigational treatment characteristics and longitudinal survival outcomes were analyzed in patients with biopsy-confirmed sarcoma enrolled in early-phase trials at MD Anderson Cancer Center from May 2006 to July 2021. Five hundred eighty-seven patients were included [405 soft tissue, 122 bone, 60 gastrointestinal stromal tumor (GIST); median of three prior lines of therapy]. Most common subtypes were leiomyosarcoma (17.2%), liposarcoma (14.0%), and GIST (10.2%). Molecular testing was available for 511 patients (87.1%); 221 patients (37.6%) were treated in matched trials. Overall response rate was 13.1% matched compared with 4.9% in unmatched (P < 0.001); the clinical benefit rate at 6 months was 43.9% vs. 19.9% (P < 0.001). Progression-free survival was longer for patients in matched trials (median, 5.5 vs. 2.4 months; P < 0.001), and overall survival was also superior for patients in matched trials (median, 21.5 vs. 12.3 months; P < 0.001). The benefit of enrollment in matched trials was maintained when patients with GIST were excluded from the analysis. Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.
Identifiants
pubmed: 37058010
pii: 725715
doi: 10.1158/1078-0432.CCR-22-3629
pmc: PMC10150251
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1708-1718Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242845
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA180964
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA273168
Pays : United States
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Lancet Oncol. 2020 Apr;21(4):508-518
pubmed: 32135080
JCO Precis Oncol. 2017;2017:
pubmed: 29082359
Cancer Chemother Pharmacol. 2011 Aug;68(2):423-9
pubmed: 21069341
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Oncotarget. 2017 Jun 13;8(24):39254-39267
pubmed: 28424409
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Clin Cancer Res. 2002 Oct;8(10):3034-8
pubmed: 12374669
Cancer. 2021 Aug 15;127(16):2934-2942
pubmed: 33910263
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e133-e144
pubmed: 34061563
Br J Cancer. 2021 Oct;125(9):1261-1269
pubmed: 34493820
Lancet Oncol. 2020 Nov;21(11):1423-1432
pubmed: 33035459
Oncologist. 2017 Dec;22(12):1518-1527
pubmed: 28835514
Cancer Discov. 2021 Nov;11(11):2780-2795
pubmed: 34112699
Nat Med. 2019 May;25(5):744-750
pubmed: 31011206
Lancet Oncol. 2016 Apr;17(4):532-538
pubmed: 26970672
Nat Rev Clin Oncol. 2018 Jul;15(7):443-458
pubmed: 29666441
Nat Rev Clin Oncol. 2020 Sep;17(9):555-568
pubmed: 32528101
Ann Oncol. 2014 Jun;25(6):1222-8
pubmed: 24608201
Cancer Treat Rev. 2020 Jun;86:102019
pubmed: 32251926
Ann Oncol. 2017 Dec 01;28(12):3000-3008
pubmed: 28950372
Clin Cancer Res. 2012 Nov 15;18(22):6373-83
pubmed: 22966018
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
JCO Precis Oncol. 2018 Nov;2:1-8
pubmed: 35135155
Curr Probl Cancer. 2021 Oct;45(5):100794
pubmed: 34656365
JAMA Oncol. 2018 Oct 1;4(10):1398-1404
pubmed: 29801054
Curr Opin Oncol. 2011 Jul;23(4):352-60
pubmed: 21519259
Eur J Cancer. 2002 Mar;38(4):543-9
pubmed: 11872347
Nat Med. 2019 May;25(5):751-758
pubmed: 31011205
JCO Precis Oncol. 2019 Apr 25;3:
pubmed: 32914012
Nat Commun. 2022 Jun 15;13(1):3406
pubmed: 35705558
ESMO Open. 2022 Apr;7(2):100425
pubmed: 35255445